Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Powered by 
Analysis
Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.56 Bn | 38.90 Bn | 2.15 Bn | 14.04% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -34.81% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | -34.93% |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.33 Bn | 334.51 Mn | 80.10% |
| 5 | Bausch Health Companies | 2.37 Bn | 528.25 Mn | 2.10 Bn | 112.75% |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 61.73% |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 4.72% |
| 9 | Fennec Pharmaceuticals | 411.43 Mn | 370.18 Mn | 17.15 Mn | 33.27% |
| 10 | RedHill Biopharma | 181.39 Mn | 181.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.04% |
| Mar 31, 2026 | 51.28% |
| Dec 31, 2025 | 32.99% |
| Sep 30, 2025 | 88.99% |
| Jun 30, 2025 | 44.40% |
| Mar 31, 2025 | 30.57% |
| Dec 31, 2024 | -22.12% |
| Sep 30, 2024 | -48.64% |
| Jun 30, 2024 | -83.43% |
| Mar 31, 2024 | 84.98% |
| Dec 31, 2023 | 45.91% |
| Sep 30, 2023 | 26.36% |
| Jun 30, 2023 | -103.91% |
| Mar 31, 2023 | -78.28% |
| Dec 31, 2022 | -141.74% |
| Sep 30, 2022 | 30.13% |
| Jun 30, 2022 | 26.11% |
| Mar 31, 2022 | -110.04% |
| Dec 31, 2021 | 62.83% |
| Sep 30, 2021 | 46.14% |